Study S003289

A Multi-center, Single-dose, Open-label, Parallel Design, Pharmacokinetics Study of BGM0504 Injection in Healthy Participants and Participants With Impaired Renal Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06929156
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 34
Start: 2025-05-06
Primary completion: 2025-12-25
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Conditions: Type 2 Diabetes Mellitus (T2DM); Overweight or Obese
Interventions: DRUG:BGM0504
Results posted: FALSE

Registered primary outcomes

Area Under the Concentration Versus Time Curve (AUC) of BGM0504 From Time Zero to Tlast (AUC0-t) [Start of Treatment up to Day 29]
Maximum Concentration of BGM0504 (Cmax) [Start of Treatment up to Day 29]
Area Under the Concentration Versus Time Curve (AUC) of BGM0504 From Time Zero to Infinity (AUC0-inf) [Start of Treatment up to Day 29]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.